
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate Inc. has demonstrated a strong capacity for innovation with its proprietary precision timed-release drug delivery platform, particularly through its ADHD treatment, CTx-1301, which has shown clinically significant improvements in the Permanent Product Measure of Performance (PERMP) with an impressive average effect size of 1.79, surpassing that of existing competitor drugs. The consistent enhancements in PERMP scores observed from just 30 minutes to 16 hours indicate the potential of CTx-1301 to reshape the ADHD treatment landscape. Furthermore, the company has strengthened its balance sheet and increased its probability of approval for CTx-1301 to 75%, indicating a robust pipeline and favorable outlook for future product candidates.
Bears say
Cingulate Inc. has significantly underperformed relative to the biotech sector, largely due to dilutive equity financings and slower-than-expected progress in its drug development pipeline. The company's stock has declined approximately 95% year-to-date, influenced by concerns over patient outcomes, challenges in market uptake of CTx-1301, and potential revenue erosion from complex patent procedures anticipated to begin in 2036. Additionally, risks associated with NDA filing delays, reliance on partnerships, and the possibility of failure in ongoing clinical studies contribute to a negative outlook for the company's financial future.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares